ArticleMolecular & cellular proteomics : MCP2017
Identification of Novel Biomarkers for Behcet Disease Diagnosis Using Human Proteome Microarray Approach.
Article in Molecular & cellular proteomics : MCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet's Disease: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Novel methods for neural IgG characterization and validation in autoimmune neurologic disorders.Journal of immunological methods · 2026Review
- Follicular helper-like γδ T cells promote plasma cell differentiation in Behçet's disease.Frontiers in immunology · 2026Article
- TheInternational journal of molecular sciences · 2025Review
- Neopterin Levels and Immune Response in Autoimmune Uveitis in an Experiment.Korean journal of ophthalmology : KJO · 2025Article
- Altered polyunsaturated fatty acids and oxylipins profile in Behçet's disease.The Korean journal of internal medicine · 2025Article
- Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray.Molecular & cellular proteomics : MCP · 2024Article
- An autoantibody profile identified by human genome-wide protein arrays in rheumatoid arthritis.MedComm · 2024Article
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.International journal of molecular sciences · 2024Review
- PhIP-Seq: methods, applications and challenges.Frontiers in bioinformatics · 2024Review
- Clinical Significance of Uncommon, Non-Clinical, and Novel Autoantibodies.ImmunoTargets and therapy · 2024Review
- Discovery and characterization of cross-reactive intrahepatic antibodies in severe alcoholic hepatitis.eLife · 2023Article
- Behçet's syndrome: recent advances to aid diagnosis.Clinical and experimental medicine · 2023Review
- Identification of Anti-SNRPA as a Novel Serological Biomarker for Systemic Sclerosis Diagnosis.Journal of proteome research · 2023Article
- Human antibody profiling technologies for autoimmune disease.Immunologic research · 2023Review
- Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet's Syndrome and Psoriatic Arthritis.International journal of molecular sciences · 2023Article
- Diagnostic value of anti-Kaiso autoantibody in axial spondyloarthritis.Frontiers in immunology · 2023Article
- Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.Cancer immunology, immunotherapy : CII · 2023Article
- Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray.Frontiers in physiology · 2022Article
- The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behcet disease (BD) is a chronic systemic vasculitis and considered as an autoimmune disease. Although rare, BD can be fatal due to ruptured vascular aneurysms or severe neurological complications. To date, no known biomarker has been reported for this disease, making it difficult to diagnosis in the clinics. To undertake this challenge, we employed the HuProt arrays, each comprised of ∼20,000 unique human proteins, to identify BD-specific autoantibodies using a Two-Phase strategy established previously. In Phase I, we profiled the autoimmunity on the HuProt arrays with 75 serum samples collected from 40 BD patients, 15 diagnosed autoimmune patients who suffer from Takayasu arteritis (TA; n = 5)), ANCA associated vasculitis (AAV; n = 5), and Sjogren's syndrome (SS; n = 5), and 20 healthy subjects, and identified 20 candidate autoantigens that were significantly associated with BD. To validate these candidates, in Phase II we constructed a focused array with these 20 candidate BD-associated antigens, and use it to profile a much larger cohort, comprised of serum samples collected from 130 BD patients, 103 autoimmune patients (i.e. 40TA, 40 AAV and 23 SS), and 110 healthy controls. This allowed us to validate CTDP1 (RNA polymerase II subunit A C-terminal domain phosphatase)as a BD-specific autoantigen. The association of anti-CTDP1 with BD patients was further validated using the traditional Western blotting analysis. In conclusion, anti-CTDP1 antibody serves a novel autoantibody for Behcet disease and is expected to help more accurate clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.